| Literature DB >> 32110278 |
Orly Ben-Nun-Shaul1, Rohit Srivastava2, Sharona Elgavish3, Shashi Gandhi2, Yuval Nevo3, Hadar Benyamini3, Arieh Eden4, Ariella Oppenheim2.
Abstract
Sepsis is an excessive, dysregulated immune response to infection that activates inflammatory and coagulation cascades, which may lead to tissue injury, multiple organ dysfunction syndrome and death. Millions of individuals die annually of sepsis. To date, the only treatment available is antibiotics, drainage of the infection source when possible, and organ support in intensive care units. Numerous previous attempts to develop therapeutic treatments, directed at discreet targets of the sepsis cascade, could not cope with the complex pathophysiology of sepsis and failed. Here we describe a novel treatment, based on empty capsids of SV40 (nanocapsids - NCs). Studies in a severe rat sepsis model showed that pre-treatment by NCs led to a dramatic increase in survival, from zero to 75%. Transcript analyses (RNAseq) demonstrated that the NC treatment is a paradigm shift. The NCs affect multiple facets of biological functions. The affected genes are modified with time, adjusting to the recovery processes. The NCs effect on normal control rats was negligible. The study shows that the NCs are capable of coping with diseases with intricate pathophysiology. Further studies are needed to determine whether when applied after sepsis onset, the NCs still improve outcome. Copyright:Entities:
Keywords: RNAseq; cellular functions; empty SV40 capsids; sepsis; signaling
Year: 2020 PMID: 32110278 PMCID: PMC7021236 DOI: 10.18632/oncotarget.27448
Source DB: PubMed Journal: Oncotarget ISSN: 1949-2553
Figure 3The effect of NCs treatments on routine lab results during disease and recovery progress.
Medians of the data collected are indicated. (A) White blood cells, (B) platelets, (C) international normalized ratio, (D) fibrinogen, (E) glutamic oxaloacetic transaminase, (F) glutamic pyruvic transaminase. The number of rats in each group is shown in parentheses. Results of the statistical analyses are presented in Supplementary Table 2. Significant pairwise comparisons are indicated by asterisks, where * corresponds to 0.05 > p > 0.01 and ** to p < 0.01.
Figure 1SV40 NCs significantly increase survival of septic rats.
Rats were injected with a total dose of 0.3 mg/kg NCs in saline (red) or Vehicle only - saline (black), divided into 3 equal aliquots and injected on 3 consecutive days, (-3,-2,-1), designated by green arrows. All the animals were operated for 2CLP on the 4th day, depicted here as day 0. Statistical analysis using Log-rank (Mantel-Cox) Test for NCs vs. Saline resulted in p = 0.0026.
Figure 2Body weight.
Rats were randomly divided into the 4 groups: Control (VO-vehicle only) - blue, Control NCs - orange, 2CLP+VO - black and 2CLP+NCs - red. Injections were performed in 3 equal daily aliquots on days -3,-2,-1, and the 2CLP insult, indicated by the purple arrow, on day 0. Following the insult both 2CLP groups showed rapid decline in weight. Rats of the 2CLP+VO group died within 24–48 hrs, indicated by **, while the 2CLP+NCs rats started re-gaining weight on day 3, and proceeded at the same rate as the controls. Each point indicates an average and standard error of 3–9 rats. The number of rats for each data point is presented in Supplementary Table 1.
Figure 4Lung sections of a 2CLP+NCs rat 4 days following the 2CLP-operation.
(A) Several groups of cells are circled. Most of these are mononuclear and have histiocytic features. They include alveolar macrophages, pneumocytes type II, dendritic cells and monocytes. Some are in alveolar septae, either within capillaries or not, while others are in alveolar spaces. Arrows point to a few cells with lobulated nuclei typical of neutrophils. (B) Black arrows point to alveolar macrophages. There are a few RBC in the alveolar spaces indicative of hemorrhage (circled). Bar size is 50 μm.
Figure 5Venn diagrams of expressed genes and enriched pathways.
RNAseq was performed on RNA extracted from lungs (3 rats each). (A) Genes and (B) Enriched pathways for lungs harvested 6 hours post insult. (C) Genes and (D) Enriched pathways for lungs harvested 24 hours post insult.
Ingenuity canonical pathways enriched (BH p-value < 0.05) only in the 2CLP+NC group
| Ingenuity canonical pathways | genes | Probability B-H (FDR) | Proposed role in the therapeutic effect of NPs | Refs | |
|---|---|---|---|---|---|
| 1 | Toll-like Receptor Signaling | 18 | 8.51E-03 | Cytokine induction and activation of iNOS | [ |
| 2 | Super-pathway of Citrulline Metabolism | 6 | 1.95E-02 | Anti-pathogen: Nitric oxide production | [ |
| 3*- | iNOS (inducible Nitric Oxide Synthetase) Signaling | 11 | 3.63E-02 | Anti-pathogen: Nitric oxide production | [ |
| 4 | CD27 Signaling in Lymphocytes | 12 | 4.47E-02 | Central immune regulation | [ |
| 5 | Role of JAK1 and JAK3 in Cytokine Signaling | 15 | 4.27E-02 | Cytokine and hormone signaling | [ |
| 6 | Role of JAK2 in Hormone-like Cytokine Signaling | 9 | 4.57E-02 | Cytokine and hormone signaling | [ |
| 7 | Role of IL-17A in Psoriasis | 6 | 1.38E-02 | Immune function: Activation of defensin | [ |
| 8 | IL-17A Signaling in Airway Cells | 18 | 1.12E-02 | Immune function: Activation of defensin | [ |
| 9*- | IL-17A Signaling in Fibroblasts | 11 | 9.55E-03 | Immune function: Activation of defensin | [ |
| 10*+ | Role of IL-17A in Arthritis | 17 | 7.59E-03 | Immune function: Activation of defensin | [ |
| 11*+ | RANK (Receptor Activator of Nf-kB) Signaling in Osteoclasts | 20 | 2.88E-02 | Nf-kB is a central regulator of inflammation and in the resolution of inflammation | [ |
| 12*+ | CD40 Signaling | 17 | 2.29E-02 | Signaling for non-canonical NF-kB. | [ |
| 13*+ | PPAR (peroxisome proliferator-activated receptor) Signaling | 19 | 2.57E-02 | Regulator of inflammatory response | [ |
| 14 | HIF1α (Hypoxia Inducible Factor) Signaling | 21 | 4.79E-02 | Metabolic reprogramming in inflammation | [ |
| 15 | Role of NANOG in Mammalian Embryonic Stem Cell Pluripotency | 29 | 5.37E-04 | Tissue/organ regeneration: Pluripotency | [ |
| 16 | Mouse Embryonic Stem Cell Pluripotency | 22 | 1.38E-02 | Tissue/organ regeneration: Pluripotency | [ |
| 17 | PCP (planar Cell Polarity) pathway | 16 | 9.33E-03 | Tissue/organ regeneration: Morphogenesis | [ |
| 18 | GM-CSF Signaling | 17 | 1.38E-02 | Bone marrow recovery | [ |
| 19*+ | Role of Tissue Factor in Cancer | 23 | 2.88E-02 | Tissue recovery: angiogenesis | [ |
| 20 | GADD45 Signaling | 8 | 7.41E-03 | Regulation of cell cycle homeostasis | [ |
| 21 | Small Cell Lung Cancer Signaling | 18 | 2.19E-02 | Cell proliferation | [ |
| 22 | Pancreatic Adenocarcinoma Signaling | 24 | 1.26E-02 | Cell proliferation and metastasis | [ |
| 23* | Ovarian Cancer Signaling | 32 | 6.92E-04 | Cell proliferation and metastasis | [ |
| 24 | PTEN (Phosphatase and tensin homolog) Signaling | 22 | 4.79E-02 | Suppressing proliferation (Tumor suppressor) | [ |
* Designates pathways that are also enriched at 24 hrs post 2CLP operation.
*- Designates that the pathway is predicted to decrease at 24 hours.
*+ Designates that the pathway is predicted to increase.